Floatz logo

Brexpiprazole

Mood Disorder

Otsuka Pharmaceutical Development & Commercialization, Inc.Small moleculePhase 3Dormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Mood Disorder cohort.

Asset / SponsorPhaseRating
QUETIAPINE
First Affiliated Hospital of Zhejiang University
Phase 4BBB
Minocycline
Pakistan Institute of Living and Learning
Phase 4BBB
Olanzapine
University of Ghana Medical School
Phase 4BBB
FLUOXETINE
University of Ghana Medical School
Phase 4BBB
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 3BB

View all 33 →

Same molecule, other indications

Brexpiprazole is also rated in:

depressive disorderActive
A
Indicative · Phase 4
82 / 100
View asset →
major depressive disorderActive
BBB
Indicative · Phase 4
75 / 100
View asset →
schizophreniaActive
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →